Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Core Insights - Ocean Biomedical, Inc. has received a patent grant from the China National Intellectual Property Administration (CNIPA) for its bispecific antibodies targeting CHI3L1 and PD1, aimed at enhancing T cell-mediated cytotoxic effects on tumor cells [1][2]. Intellectual Property and Market Position - The newly issued patent strengthens Ocean Biomedical's intellectual property portfolio and provides protection in one of the largest pharmaceutical markets globally [2][5]. - The granted claims cover the novel design and therapeutic applications of bispecific antibodies that inhibit CHI3L1 and PD1, which are crucial in immune evasion by tumor cells [2][3]. Technological Innovation - Ocean Biomedical's bispecific antibody technology represents a potential paradigm shift in cancer immunotherapy by targeting both CHI3L1 and PD1, which may enhance the immune system's ability to combat tumors more effectively than existing treatments [3][4]. - This dual-targeting approach could lead to more durable responses and better patient outcomes by blocking two key pathways that tumors use to suppress the immune response [4]. Strategic Vision - The patent grant is viewed as a significant milestone in the company's global expansion strategy, highlighting the novelty and therapeutic potential of its bispecific antibody platform [4]. - Ocean Biomedical is committed to leveraging its robust patent estate to drive the development and commercialization of novel immunotherapies [5][6]. Collaboration and Development - The company plans to continue collaborating with leading researchers, biopharma partners, and regulatory agencies to accelerate the translation of its discoveries into transformative therapies [6].